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Interferon-inducible gene 202b controls CD8
þ
T cell-mediated suppression in anti-DNA Ig
peptide-treated (NZB NZW) F1 lupus mice
R Dinesh, BH Hahn, A La Cava and RP Singh
Division of Rheumatology, Department of Medicine at the David Geffen School of Medicine, University of California Los Angeles,
Los Angeles, CA, USA
Administration of an artificial peptide (pConsensus) based on anti-DNA IgG sequences that contain major histocompatibility
complex class I and class II T-cell determinants, induces immune tolerance in NZB/NZW F1 female (BWF1) mice.
To understand the molecular basis of CD8
þ Ti-mediated suppression, we previously performed microarray analysis to identify
genes that were differentially expressed following tolerance induction with pCons. CD8
þ T cells from mice tolerized with pCons
showed more than two-fold increase in Ifi202b mRNA, an interferon inducible gene, versus cells from untolerized mice. Ifi202b
expression increased through weeks 1–4 after tolerization and then decreased, reapproaching baseline levels at 6 weeks.
In vitro polyclonal activation of tolerized CD8
þ T cells significantly increased Ifi202b mRNA expression. Importantly, silencing
of Ifi202b abrogated the suppressive capacity of CD8
þ Ti cells. This was associated with decreased expression of Foxp3, and
decreased gene and protein expression of transforming growth factor (TGF)b and interleukin-2 (IL-2), but not of interferon
(IFN)-g, IL-10, or IL-17. Silencing of another IFN-induced gene upregulated in tolerized CD8
þ T cells, IFNAR1, had no effect on
the ability of CD8
þ T cells to suppress autoantibody production. Our findings indicate a potential role for Ifi202b in
the suppressive capacity of peptide-induced regulatory CD8
þ Ti cells through effects on the expression of Foxp3 and the
synthesis of TGFb.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by multiorgan damage and a
variety of clinical symptoms associated with the produc-
tion of autoantibodies against dsDNA and other nuclear
and cytoplasmic antigens. The pathogenesis of SLE is
contingent on a variety of factors that are environmental,
genetic and hormonal in nature.
1
The induction of T cells with regulatory and suppres-
sive capacity has been suggested as a novel therapy to
control the activities of pathogenic T cells and Th-cell-
mediated B-cell production of antibodies responsible
for disease.
2–4 The inhibitory capacity of CD4
þ T
regulatory cells (Tregs), which suppress through a
cell contact dependent mechanism, and CD8
þT regula-
tory cells (CD8
þ Ti), which suppress through both
secretion of anti-inflammatory cytokines and cell-contact
dependent mechanisms, has been demonstrated in
several experimental models of autoimmune diseases,
including SLE.
5,6
Recently, peptide-induced expansion of the T-cell
regulatory compartment has been considered as a novel
strategy in the treatment of SLE and other autoimmune
conditions.
7–9 We have shown previously that treatment
of 12–16-week-old (NZB/NZW) BWF1 mice with pCons,
a tolerogenic peptide based on the major histocompat-
ibility complex class I and II determinants of the Vh
region of IgG antibodies against double-stranded DNA,
induces both subset of CD4
þ CD25
þ Tregs as well as a
subset of CD8
þ Ti.
2,10 Concomitant with this increase in
regulatory cells, tolerized BWF1 mice had increased
survival, delayed onset of lupus nephritis, and decreased
CD4
þ Th production of interferon (IFN)-g.
7,11 We
showed previously that mice treated with pCons have
an expansion of the CD8
þ T-cell compartment, and that
these tolerized CD8
þ Ti are capable of suppressing both
CD4
þ T-effector cell responses and B-cell responses in
a contact-independent manner.
4,11,12 In addition, both
Foxp3 expression and transforming growth factor (TGF)b
secretion were shown to be necessary for the suppressive
capacity of pCons-induced CD8
þ Ti.
4
The molecular mechanisms that determine whether
Tcells will differentiate into helper or regulatory cells are
incompletely understood. Cell fate decisions depend
on T-cell expression of certain genes, such as T-bet for
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13 RORgt for Th17 effector T
cells,
14 GATA-3 for CD4
þ Th2 cells
15 and Foxp3 for
regulatory CD4
þ and inhibitory CD8
þT cells.
4,10,16
Several groups have used microarray analysis to study
differential gene expression patterns in the peripheral
blood cells of SLE patients and healthy controls.
17,18
Increased interferon gene signatures have been found in
a high proportion of SLE patients.
18–20 In addition,
interferon genes are thought to be mediators of
autoimmune diseases, such as SLE. Both beneficial and
detrimental effects of IFN genes have been described.
Interferon inducible gene 202 (Ifi202) and its gene
cluster have been implicated in the apoptosis of B cells
and in the pathogenesis of SLE.
21,22 In NZB/NZW
mice, type I interferon receptor deficiency has been
linked to a reduction in SLE symptoms.
23 Recently,
it has been shown that the candidate lupus susceptibility
gene Ifi202a is largely dispensable for B-cell
function.
24 Thus, the role of interferon genes is context
dependent and much more complex than previously
thought.
In our model of immune tolerance, the molecular
mechanisms responsible for inducing suppressive capa-
city in Tcells after Ig peptide-induced tolerance have not
been well defined. As we found increased Ifi202b gene
expression in CD8
þ Ti cells after pCons treatment,
25 we
wanted to determine whether silencing/blocking of
Ifi202b would uncover a role for Ifi202b in the suppres-
sion of autoantibody production by CD8
þ Ti in our
system. In this study, we identify a novel role for Ifi202b
in pCons-induced tolerance, show that silencing of
Ifi202b in CD8
þ Ti cells leads to increased anti-DNA
antibody (Ab) production by B cells as well as reduced
gene and protein expression of Foxp3 and TGFb in
CD8þ T cells, which are required to suppress target
CD4
þ CD25
  helper T cells and B cells.
Results
Ifi202b mRNA expression is increased in CD8
þ T cells for
at least 4 weeks after pCons tolerization in BWF1 mice
By microarray analysis, we found that gene expression
of Ifi202b was significantly upregulated in the splenic
CD8
þ Ti induced after tolerance induction with pCons.
25
To determine whether pCons treatment affected the
expression of Ifi202b over time, we isolated splenic
CD8
þTcells from naı ¨ve (nCD8) or tolerized (tCD8) mice
at different time points following tolerization (2, 4, and
6 weeks) and examined Ifi202b mRNA expression by
real-time PCR. These time points were selected because
functional tolerance is induced within 2 weeks of
injections. As shown in Figure 1a, Ifi202b mRNA was
increased at 2–4 weeks after pCons treatment and then
by week 6 had returned to near basal levels in tolerized
CD8
þ T cells (Figure 1a, column 2 and 3). These data
suggest that pCons treatment induces Ifi202b expression
transiently, with an initial upregulation followed by a
decrease toward basal levels.
Expression of Ifi202b in untreated naı ¨ve BWF1 mice in T and
B cells
As BWF1 mice develop lupus-like nephritis sponta-
neously by 50 weeks of age, and to better understand the
normal pattern of Ifi202b gene expression, we next tested
splenic subsets (CD8, CD4 and B cells) from untreated
BWF1 females of varying ages (6, 20 and 50-week-old
mice). Ifi202b mRNA expression in naı ¨ve CD8
þ T cells
and naı ¨ve CD4
þ T cells did not differ at 6 and 20 weeks
of age, but fell significantly in CD4
þ T cells from 50-
week-old nephritic mice (Figures 1b and c). In contrast,
in splenic B cells, the mRNA of Ifi202b increased
significantly over time (Figure 1d). These data suggest
that the early increase in Ifi202b expression in CD8
þ
Ti cells induced by tolerance with pCons is unique,
in contrast to BWF1 B cells, which naturally display
increased expression of Ifi202b over a period of months
as disease develops and progresses.
Ifi202b protein expression was increased after pCons tolerance
Ifi202b protein expression was increased significantly in
tolerized (2–4 weeks after pCons tolerization) CD8
þ Ti
cells compared with naı ¨ve CD8
þ T cells as determined
by western blot analysis (Figure 1e). Ifi202b protein
expression was also increased in tolerized B cells and in
total splenocytes (Figures 1f and g). These data indicate
that pCons induces Ifi202b protein concomitantly with
induction of tolerance in multiple hematopoietic cell
lineages.
Tolerized CD8
þ T cells suppress autoAb production up to 6
weeks after pCons treatment
Since we have shown previously that CD8
þ Ti suppress
anti-DNA Ab production after 1 week of pCons treat-
ment,
11,12 and because Ifi202b expression is still elevated
at 4 weeks, we investigated if suppression still occurs at a
later time point. As shown in Figure 2, splenic CD8
þ T
cells obtained 6 weeks after pCons treatment still
suppressed anti-DNA Ab production (compare column
3–2, Po0.04). Silencing of Ifi202b abrogated the suppres-
sion of anti-DNA Ab at both 6 weeks after tolerization
(Figure 2, compare column 4–3, Po0.02) and at 2 weeks
after tolerization (Figure 3a compare column d to e,
Po0.04). Thus, pCons-induced CD8
þ Ti can suppress
autoreactivity for at least 6 weeks after a single tolerizing
injection.
Silencing of Ifi202b with siRNA abrogates suppression
of anti-DNA induced by CD8
þ Ti cells
An increased interferon-inducible gene signature has
been found in SLE patients.
18,20 We were interested to see
whether silencing/blocking interferon-induced genes
had any effects on CD8
þ Ti-mediated suppression of
autoantibody production in our system. The role of
Ifi202b in the suppressive capacity of CD8
þ Ti was tested
at 2 and 6 weeks after tolerization using the ability of the
cells to suppress anti-DNA production in vitro as a
measure. To identify the suppressive mechanisms used
by CD8
þ Ti cells from tolerized mice, we purified splenic
CD8
þ T cells from saline or negative control peptide-
treated naı ¨ve and pCons-tolerized mice, and transfected
them with small interfering RNA (siRNA) for Ifi202b or
IFNAR1. Then, non-transfected or transfected CD8
þ
T cells were cultured with CD4
þ T cells plus B cells
from 12–16 week-old naı ¨ve BWF1 mice. After 4–5 days,
culture supernatants were collected and measured for
anti-DNA IgG by enzyme-linked immunosorbent
assay (ELISA). We found a significant suppression of
anti-DNA Ab production when CD8
þ T cells from
tolerized mice (tCD8) were added to the cultures
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þ helper T cells plus B cells from naı ¨ve
mice (Figure 3, compare column d (with arrow) to
column c, Po0.03). The siRNA of Ifi202b abrogated
suppression induced by tolerized CD8
þT cells signifi-
cantly (Figure 3a, compare column e to column d (with
arrow), Po0.04). The siRNA for IFNAR1, the control
siRNA of GAPDH, scrambled siRNA and the amine
did not change the suppressive capacity of tolerized
CD8
þ T cells (compare column d to columns g–i). These
data indicate that CD8
þ Ti cells from pCons-treated mice
suppress anti-DNA production in an Ifi202b-dependent
manner.
Silencing of Ifi202b significantly reduces protein levels of
Ifi202b
As we have found that Ifi202b silencing reduces the
expression of Ifi202b mRNA, to confirm reduction of
protein levels, we conducted western blot analyses of cell
lysates from tolerized CD8
þ Ti cells with and without
siRNA of Ifi202b. As shown in Figure 3b, silencing of
Ifi202b does in fact, significantly reduce Ifi202b protein
levels (Figure 3b tCD8 vs tCD8þIFI202b siRNA 100nM
Po0.0004, tCD8vs tCD8þIFI202b 50nM, Po0.011).
Furthermore, scrambled siRNA did not change Ifi202b
protein expression significantly (Figure 3b, lane 4). These
Figure 1 (a) Ifi202b mRNA expression is dynamic after pCons tolerization in BWF1 mice. Saline or negative control peptide-treated naı ¨ve
CD8
þ Tcells and pCons-tolerized CD8
þ Tcells (1–2 10
6 cells) were isolated from BWF1 mice splenocytes at different times (2, 4 and 6 weeks
after pCons treatment). RNA was isolated and real-time PCR was performed with murine Ifi202b primers and probes. An Ifi202b standard
curve was created and the relative input amount was calculated. GAPDH was used as a housekeeping gene. Results are shown from three
independent experiments from 3 to 5 mice in each group. Horizontal lines indicate means. **Po0.001, *Po0.03, statistically significant. (b–d).
Expression of Ifi202b changes spontaneously in spleen cells of BWF1 mice with age and development of disease, starts to decrease at 50 weeks
of age in CD4
þ Tcells, and exhibits little to no change in CD8
þ Tcells. In contrast, in B cells, Ifi202b increases spontaneously until the 50th
week of age. CD4
þ Tcells, CD8
þ Tcells and B cells were isolated from spleens of 3–5 unmanipulated BWF1 females at different ages (6, 20,
and 50 weeks of age). RNAwas isolated and real-time PCR was performed. Data shown are from three experiments. (e–g). Ifi202b protein was
increased after pCons tolerance. Western blot analyses were performed with Ifi202b-specific antibody using cell lysates from CD8
þ
Tcells, B cells and splenocytes from naı ¨ve and pCons-treated mice (3–5 mice in each group). The b-actin was used for normalization purposes
in the densitometry analyses.
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both mRNA and protein levels of Ifi202b.
Silencing of Ifi202b reduces Foxp3 expression in tolerized
CD8
þ Ti cells
To test the effect of silencing Ifi202b on Foxp3 expression
in tolerized CD8
þ Ti cells, we isolated CD8
þ Tcells from
naive and tolerized BWF1 mice and transfected them
with Ifi202b siRNA or a scrambled siRNA control and
cultured the cells for 48–72h. Real-time PCR analysis
demonstrated that tolerized CD8
þ T cells have higher
Foxp3 mRNA compared with naive CD8
þ T cells
(Figure 4). We have shown earlier that pCons treatment
induces distinct CD8
þ Ti cells and these cells are
expanded and enriched in Foxp3 expression both at
mRNA and at protein levels.
11,12 Importantly, Ifi202b
silencing reduced expression of Foxp3 mRNA in
tolerized CD8
þ T cells (Figure 4).
Silencing of Ifi202b in tolerized CD8
þ Tcells does not impact
secretion of IFNg, IL-10, or IL-17
We found that tolerization with pCons significantly
increased interleukin-2 (IL-2) and IFN-g production in
the supernatant of CD8
þ Ti cells, and further went on to
determine whether Ifi202b silencing had any effect on
cytokine production. As shown, we also found that IL-2
and IFN-g levels were decreased after Ifi202b silencing,
and these differences were statistically significant
(Figures 5a and b). As we had not previously investi-
gated the role of CD8
þ Ti- produced IL-10 in our system,
we also examined IL-10 production. Silencing of Ifi202b
did not affect expression or secretion of IL-10 (Figure 5c).
Recently, the role of IL-17 has been demonstrated in
many inflammatory and autoimmune diseases including
SLE.
26–28 Therefore, we evaluated whether pCons-in-
duced tolerance had any effect on IL-17 production in
CD8
þ Ti cells. We found that tolerized CD8
þT cells
produce significantly less IL-17 compared with naı ¨ve
CD8
þ T cells (Figure 5d). However, silencing of Ifi202b
had no effect on IL-17 secretion by tolerized CD8
þ
Tcells. These data indicate that the Ifi202b gene does not
affect CD8
þ Ti cell secretion of IFNg, IL-10, or IL-17.
Silencing of Ifi202b in tolerized CD8
þ Tcells decreases TGFb
expression
As pCons-reactive CD8
þ suppressor Tcells require TGFb
secretion for their effect,
11,12 we determined whether
silencing of either Ifi202b or IFNAR1 had any effect on
TGFb expression in tolerized CD8
þ Ti cells. We cultured
tolerized CD8
þ Ti cells, transfected them with Ifi202b,
IFNAR1, or control siRNA for 48–72h. RNAwas isolated
from cultures and real-time PCR was performed. As
shown in Figure 6a, silencing of Ifi202b in tolerized
CD8
þ T cells significantly decreased TGFb mRNA
expression. In contrast, there was no change in TGFb
expression in IFNAR1-silenced CD8
þ Tcell cultures and
in splenocytes (data not shown). These findings indicate
that IfI202b, but not IFNAR1 is required for TGFb
transcription in CD8
þ Ti cells.
To determine whether silencing of Ifi202b affects
protein expression of TGFb in tolerized CD8
þ Ti cells,
we tested TGFb levels in the culture supernatants of
naı ¨ve, or tolerized CD8
þ Ti cells transfected with Ifi202b
siRNA or scrambled control siRNA. As shown in
Figure 6b, silencing of Ifi202b reduced the secretion of
TGFb significantly. In a separate experiment, splenocytes
were transfected with Ifi202b siRNA as indicated above,
cell lysates were prepared and western blots performed
with anti-TGFb Ab. As shown in Figures 6c–e, silencing
of Ifi202b reduced TGFb protein levels. As TGFb signals
through SMADs, we next determined whether Ifi202b
silencing affects SMAD expression. Tolerized splenocytes
had increased Smad2 and Smad3 expression, and we
found that silencing of Ifi202b decreased Smad2 and
Smad3 expression (Figure 6f), supporting our hypothesis
that Ifi202b affects the TGFb pathway. These data further
suggest a link between Ifi202b expression and the
production of TGFb.
Discussion
CD8
þ T cells appear to be important for immune
regulation in SLE. Regulatory CD8
þ T cells help
maintain tolerance to self antigens, and recent evidence
indicates that a loss of CD8
þ T cell suppressive function
contributes to disease progression in both murine and
human SLE.
29–31 As BWF1 mice age, their CD8
þ T cells
become defective.
29 However, in BWF1 mice treated with
pCons, some CD8
þ T cells become Foxp3
þ inhibitory
cells; they downregulate autoantibody production and
delay the onset of nephritis.
4,11,12 In addition, they
suppress the onset of disease when adoptively trans-
ferred to syngeneic BWF1 mice.
11 A major mechanism of
their suppressive effect is the secretion of TGFb. Previous
Figure 2 Tolerized CD8
þ Tcells suppress autoantibody production
at 6 weeks after pCons treatment. CD8
þ T cells were isolated 6
weeks after pCons treatment and cells were cultured with naı ¨ve
CD4 T cells and B cells (Spleens were pooled from 3 to 4 mice per
group). After 3–4 days, the culture supernatants were collected and
anti-DNA was measured by ELISA. Tolerized CD8
þ Ti suppress
anti-DNA production significantly (column 3 compare with column
2, Po0.04, paired one-tailed test); that suppression was lost after
silencing of Ifi202b (column 4), *Po0.02 by paired two-tailed test,
nBþnCD4þtCD8 vs nBþnCD4þtCD8þIfi202b siRNA. Each dot
represents data from each experimental replicate and the horizontal
bar denotes means. Data shown are individual results from four
independent experiments.
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þ Ti cells can
suppress the proliferation of syngeneic CD4
þ CD25
 
T cells and of B cells.
4,12 Here, we expanded upon data
derived during a previous microarray experiment to
understand the molecular basis of the suppressive
capacity of CD8
þ Ti cells from tolerized animals.
25 Our
data suggest that the changes in gene expression in
CD8
þ Ti cells from tolerized mice include an upregula-
tion of Ifi202b, which we show here is a major participant
in the suppressive function of CD8
þ Ti.
This is the first report of the effects of upregulated
Ifi202b in CD8
þ Ti cells after administration of the
tolerogenic peptide pCons into BWF1 mice. Silencing
of Ifi202b in tolerized CD8
þ Ti cells abrogated the
suppressive capacity of these cells, and reduced
their production of TGFb. The pCons tolerance did
reduce IL-17 production in CD8
þTi cells compared with
naı ¨ve CD8
þ Tcells (Figure 5d). Our results are consistent
with others who have demonstrated reduced IL-17 levels
in splenocytes from lupus-prone SNF1 mice (New
Zealand black SWR F1) following induction of toler-
ance with histone-derived peptides
32 or with nasal
administration of anti-CD3.
33 However, silencing of
Ifi202b did not affect IL-17 production in tolerized
CD8
þ T cells, and therefore, it appears that IL-17 is not
regulated by the Ifi202b gene. Ifi202b silencing reduced
expression of Foxp3 in the tolerized CD8
þ T cells. These
data indicate that Ifi202b and Foxp3 expression are
related, which is consistent with our earlier work in
which upregulation of Foxp3 has been shown to be a
reliable marker of the suppressive capacity of regulatory
CD8
þ T cells.
11
The role of Ifi202b in the suppressive functions of
CD8
þ Ti cells is particularly interesting as there is
substantial evidence that expression of interferon-
Figure 3 (a) Silencing with siRNA of Ifi202b abrogates suppression of anti-DNA induced by CD8
þ Ti cells. CD8
þ Tcells were isolated from
pCons-treated mice 1–2 weeks after pCons tolerization and the cells were transfected with either Ifi202b siRNA, IFNAR1 siRNA, or control
siRNA, as described in the Materials and methods section. Then, non-transfected and transfected CD8
þ T cells (1 10
5) were cultured with
CD4
þ T cells (1 10
5) and B cells (1 10
4) from naı ¨ve BWF1 mice. After 4–5 days, culture supernatants were collected and measured for
anti-DNA IgG with ELISA. Tolerized CD8¼tCD8; Naı ¨ve CD8¼nCD8. Columns: a, nCD4; b, nB; c, nCD4þ nB; d, nCD4þnBþtCD8; e,
nCD4þnBþtCD8þIfi202b siRNA; f, nCD4þnBþtCD8þIFNAR1siRNA; g, nCD4þnBþtCD8þsi port Amine; h, nCD4þnBþ
tCD8þGAPDH siRNA; i, nCD4þnBþtCD8þGAPDH-negative siRNA or scrambled siRNA with no homology to mouse, rat or human
genomes. Data shown are from three to four independent experiments. (b) Silencing of Ifi202b reduces Ifi202b protein. Tolerized CD8
þ Tcells
(2–3 10
6cells) were isolated and cultured with and without siRNA of Ifi202b (100, 50nM, scrambled siRNA (100nM)) for 48–72h. Cell lysates
were prepared and western blot was performed with Ifi202b and b-actin antibody as described in Materials and methods. Densitometry was
performed (***Po0.0004 tCD8 vs tCD8þIFI202b siRNA 100nM.* Po0.011 tCD8 vs tCD8þIFI202b siRNA 50nM). Densitometry data shown
are combined from five experiments.
Figure 4 Silencing of Ifi202b reduces Foxp3 expression in tolerized
CD8
þ Tc e l l s .N a ı ¨ve and tolerized CD8
þ T cells from 3 to 5 in each
group were isolated and cultured as shown previously with Ifi202b
siRNA and scrambled siRNA. RNA was isolated and equal amounts
(100ng) of RNAwere used for real-time PCR with Foxp3 primers and
probes (TaqMan—Applied Biosystems). Values were normalized to
GAPDH. Paired one-tailed or two-tailed test was used. Po0.05 were
considered significant. Data shown are from three experiments.
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pheral blood cells of SLE patients, particularly those
with active clinical disease and nephritis.
17–19 In mice, the
influence of type I IFN depends on the strain studied.
SLE was prevented or reduced in NZB mice in which
IFNAR1, the RI receptor for type I IFNs such as IFNa,
was knocked out.
23 In contrast, knockout of the RI
receptor in MRL/lpr mice worsened autoimmune dis-
ease.
34 The potential of type I IFNs to protect from
autoimmunity in MRL/lpr was further shown by a
reduced synthesis of Ig by B cells activated with anti-
CD40L in the presence of type I IFNs.
34 Administration
of IFNa accelerated disease in BWF1 mice, but not in
BALB/c mice.
35 IFN-a kinoid vaccine-induced neutraliz-
ing antibodies have been shown to reduce lupus
manifestations, including proteinuria and renal lesions.
36
A microarray analysis of spleen cell RNA showed that
among 11000 genes analyzed, Ifi202 and Ifi203 were
dysregulated in the congenic B6.Nba2 strain compared
with the B6 strain.
22 Consistent with our data, Ifi202
was highly overexpressed in B cells from naı ¨ve mice.
As Ifi202 expression correlates with resistance to
apoptosis,
22 upregulated Ifi202 may confer substantial
susceptibility to SLE because of increased autoreactive
B-cell survival. However, we could not demonstrate a
role for Ifi202b in resistance to apoptosis in CD8
þ Tcells,
so that property probably depends on the cell type or
possibly interactive regulation by other genes, including
others in the Ifi202 family.
Secretion of TGFb is a major mechanism by which
CD8
þ Ti cells suppress autoreactive T and B cells. Thus,
the ability of Ifi202b to increase TGFb production is
evidence that upregulation of Ifi202b in these cells
augments their immunosuppressive capacity. That
capacity is retained for several weeks after tolerization.
It seems likely that both Ifi202b and Foxp3 are
important in suppression in this model of CD8
þ T-cell
tolerance. In contrast to these findings, there was no
evidence that the interferon-inducible gene IFNAR1 has
a role in the suppressive capacity of tolerant CD8
þ Tcells
in our system, even though expression of that gene is
upregulated.
Figure 5 (a) Silencing of Ifi202b in tolerized CD8
þ T cells decreases IL-2 protein secretion. Naı ¨ve and tolerized CD8
þ Tcells (1 10
5) were
cultured as shown previously with Ifi202b siRNA and scrambled siRNA. Culture supernatant was obtained and IL-2 secreted protein was
measured by ELISA as per manufacturer’s instructions (Biolegend Inc.). An IL-2 standard curve was created and unknown values were
determined. Data shown are from two to four experiments. Error bars indicate s.e.m. Paired one or two-tailed t-test was used. *Po0.01
considered as significant. (b) Silencing of Ifi202b in tolerized CD8
þ T cells decreases IFN-g protein secretion. IFN-g secreted protein was
measured from the above culture using an IFN-g mouse ELISA kit from BD Biosciences (San Diego, CA, USA) as per manufacturer’s
instructions. An IFN-g standard curve was created and values were analyzed. Data shown are from two experiments. (c) Silencing of Ifi202b
in tolerized CD8
þ T cells does not change IL-10 protein secretion. IL-10 protein was measured from the above culture by ELISA as per
manufacturer’s instructions. Data shown are from two experiments. (d) Tolerized CD8
þ T cells have reduced IL-17 secretion and Ifi202b
silencing has no effect on IL-17. IL-17 was measured from the above culture supernatant using an ELISA kit from Biolegend as per
manufacturer’s instructions. An IL-17 standard curve was created and values were analyzed. Data shown are from three experiments.
*Po0.03 considered as significant.
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suppressive capacity of peripheral CD8
þ T cells in our
model of tolerance. Future study will be required to
understand how this gene interacts with other genes,
together or independently, to affect the suppressive
capacity of CD8
þ T cells and whether this gene has
differential effects in specific immune cell subsets.
Materials and methods
Mice
NZB (H-2
d/d), NZW (H-2
z/z) and (NZB NZW) F1
(H-2
d/z) mice were bred and maintained at the
University of California Los Angeles or purchased from
The Jackson Laboratories (Bar Harbor, ME, USA).
All mice were housed in pathogen-free conditions and
were treated in accordance with the guidelines of the
University of California Los Angeles Animal Research
Committee, an Institution accredited by the Association
for Assessment and Accreditation of Laboratory Animal
Care. All experiments were conducted in female mice.
Peptides
The peptides used in this study, their sources and
the major histocompatibility complex molecules they
bind are described in detail elsewhere.
11 The tolerizing
peptide pCons (FIEWNKLRFRQGLEW) is artificial;
it contains T-cell determinants based on the J558 VH
regions of several murine mAb anti-dsDNA from BWF1
mice.
37–39 Peptide p58 (FYNQKFKGKATL) was used as a
negative-control peptide.
Treatment of mice
The 10–12-week-old BWF1 mice were tolerized by
a single intravenous dose of 1mg of pCons or negative-
control peptide, dissolved in saline, as reported
previously.
4,7,11,12
Cell isolation and staining
Spleen cells were isolated from tolerized BWF1 mice,
negative Ig-derived control peptide (p58)-treated
Figure 6 Silencing of Ifi202b in tolerized CD8
þ T cells decreases TGFb expression. (a) Tolerized CD8
þ Tcells (2–3 10
6cells) were isolated
and cultured with and without the siRNA of Ifi202b or IFNAR1 (50nM) for 48–72h. RNAwas isolated from these cultures and real-time PCR
was performed. Silencing of Ifi202b in tolerized CD8
þ T cells decreased TGFb expression (*Po0.04 nCD8 vs tol CD8, **Po0.003 tCD8 vs
tCD8þIfi202b si RNA, paired two-tailed t-test). Error bars indicate s.e.m. Each dot represents data from each experimental replicate and the
horizontal bar denotes means. Data shown are from two independent experiments performed. (b, c) IFI202b silencing reduced TGFb mRNA
and protein expression. TGFb was measured from culture supernatant from naı ¨ve and tolerized CD8
þ T cells with and without siRNA
treatment. Each sample was run in duplicate and the values were determined from the standard curve of TGFb. Silencing of Ifi202b
significantly reduced TGFb,* Po0.018, paired two-tailed t-test. Error bars denote s.e.m. Compare tolerized CD8
þ Tcells vs tolerized CD8
þ T
cellsþIfi202b siRNA. Data shown are from five experiments. (c) TGFb mRNA was determined by real-time PCR as described previously.
(d) Immunoblots were assayed from cell lysates prepared from splenocytes with and without siRNA treatment as above. Equal amount of
protein (10–15mg) was loaded in each well. Gels were transferred to a polyvinylidene fluoride (PVDF) membrane and immunoblotted with
TGFb and b-actin-specific antibodies. Lane 1—naı ¨ve splenocytes, lane 2—tolerized splenocytes, lane 3—tolerized splenocytes þ Ifi202b
siRNA, lane 4-tolerized splenocytes þ scrambled siRNA. (e) Densitometry analysis of mature TGFb normalized to b-actin. Po0.01 by paired
two-tailed t-test. (f) Smad 2 and smad 3 mRNA expressions were determined by real-time PCR. Error bars denote s.e.m. Values were
normalized to GAPDH.
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the administration of pCons as described earlier.
11
Briefly, red blood cells were lysed with ACK
lysing buffer (Sigma, St Louis, MO, USA). Cell subsets
were purified following incubation with anti-CD4,
anti-B220, or anti-CD8 microbeads (from Miltenyi
Biotech, Auburn, CA, USA). Purities of cells were more
than 90% as assessed by flowcytometry. Antibodies
anti-CD4, anti-B220 and anti-CD8 (all from BD Pharmin-
gen, San Diego, CA, USA) was used to FACS analyze
the cells.
Measurement of anti-DNA Ab
Anti-DNA Ab was determined as described earlier.
2,7,11
Briefly, naı ¨ve B, CD4
þT and CD8
þ T cells were isolated
and cultured with tolerized CD8
þ T cells as described
previously.
11 CD8
þ T cells were transfected with siRNA
of the gene of interest and scrambled siRNA controls. B
cells were obtained from old nephritic BWF1 mice. The
ratio of naı ¨ve B to naı ¨ve CD4
þ T cells was 1:10 and for
naı ¨ve or tolerized CD8
þ T cells was 1:1. After 3–4 days,
cultured supernatant was obtained and analyzed for
anti-DNA Ab by ELISA.
IL-2, IFN-g, IL-10 and IL-17 measurement
Protein levels of IL-2, IL-10 and IL-17 were measured in
culture supernatants from transfected and non-trans-
fected CD8
þ T cells by mouse ELISA set kits (Biolegend
Inc., San Diego, CA, USA) as per manufacturer’s
instructions.
TGFb protein measurement
TGFb protein was measured in culture supernatant from
transfected CD8
þ T cells and splenocytes using a mouse
TGFb immunoassay ELISA kit (R&D Systems, Minnea-
polis, MN, USA). Culture supernatants were treated
with 1N HCL to activate latent TGFb and were later
neutralized by 1.2N NaOH. The sensitivity limit for TGFb
was 4.6pgml
 1. The TGFb standard curve was created
and the value of test samples was determined.
Western blot analysis
Cell lysates were prepared from CD8
þ Ti cells and
splenocytes, cultured in vitro with and without siRNA.
Cells were lysed with RIPA buffer (150nM NaCl, 1.0%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10mM Tris,
pH 7.3) supplemented with Protease Arrest (Cat no. 786–
108) protease inhibitor cocktail solution (G Biosciences,
Maryland Heights, MO, USA). Protein was measured
from each sample using the Bradford assay (Bio-Rad
Laboratories, Hercules, CA, USA) and an equal amount
of protein was loaded in each well. The lysates were
resolved on a 4–12% NuPage gel (Invitrogen, Carlsbad,
CA, USA) in reducing conditions. Proteins were electro-
transferred onto a polyvinylidene fluoride membrane
(Invitrogen). The membranes were blocked with 3% BSA
and immunoblotted with a specific antibody (Ifi202,
1:200 dilution, from Santa Cruz Biotechnology; TGFb,
1:500 dilution, from BD Pharmingen, San Diego, CA,
USA; and b-actin, 1:100000 dilution from Sigma).
Following washing, the membranes were incubated in
secondary antibodies diluted 1: 2500 (Santa Cruz Inc,
Santa Cruz, CA, USA). All blocking, incubation and
washing steps were performed in TBST (TBS and 0.1%
Tween 20). Proteins were visualized using ECL (GE
Healthcare, Buckinghamshire, UK).
Real-time PCR
Real-time PCR was analyzed as described earlier.
4,11 Total
cellular RNA was isolated from total white blood cell or
different cell subsets of saline-treated naive or pCons
tolerized BWF1 mice with TRIzol (Invitrogen) as per
manufacturer’s protocol. Spleen cells from two to three
mice in each group were pooled for each experimental
group. Total RNA, 100ng, was used with one step
RT-PCR reagents from Applied Biosystems. The follow-
ing primers and probe combinations were used for
Ifi202b. Ifi202b forward primer: 30-CCGGGAAACAC
CATTGCTT-50; Ifi202b reverse primer: 30-ACCTCAGA
CACGCTGGAATATTC-50; TaqMan Probe: 30-ATCAGAT
TATTTTGGTATGTATGGGTCTCTGGCAA-50 (Applied
Biosystems). The primer and probe combinations of TGFb
and Foxp3 have been described earlier.
4,11 The amplifica-
tion primers were at 900nM and the probe at 200nM.F o r
relative quantitation, a standard curve was constructed for
each primer and probe set, using total RNA. GAPDH was
used as an endogenous control in each experimental set.
All samples were run in duplicate.
siRNA transfection
The siRNA transfection has been described earlier.
4,11,12
Briefly, CD8
þ T cells isolated as described above were
plated and cultured for 24h in 12–24 well plates in
complete medium containing 10% FCS. For transfection,
Silencer siRNA Transfection Kit from Ambion (Austin,
TX, USA) was used. The siPORT amine was diluted
using OptiMEM reduced serum medium (Gibco Invitro-
gen Corporation, Carlsbad, CA, USA). Validated siRNA
of Ifi202b, IFNAR1 and GAPDH was obtained from
Ambion, as well as positive and negative-siRNA
controls. The negative-control siRNA was a scrambled
sequence that bears no homology to mouse, rat, or
human genomes, and the transfection agent alone served
as another control (siPORTamine). The agent was mixed
with siRNA of Ifi202b, IFNAR1, GAPDH, or controls (50–
100nM) in serum-free medium and incubated at room
temperature for 30min. Cells were transfected with
siRNA complexes as described earlier.
4,11,12 Supernatants
were obtained for measurement of anti-DNA Ab. In
some experiments, cells were lysed with TRIzol (Invitro-
gen) for RNA isolation, and total-cell lysates were
prepared with RIPA lysis buffer for western blot analysis.
Statistical analyses
Prism 4 software (GraphPad, San Diego, CA, USA) was
used to perform all statistical analyses. Comparisons
between two groups were performed by paired two-
tailed, one-tailed t-test, or the Mann–Whitney U-tests.
Comparisons between more than two groups were
performed by analysis of variance (ANOVA). P-values
o0.05 were considered significant.
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